TIM-3 blockade in vivo, particularly combined with PD-1 blockade, has shown encouraging results, as evidenced by restoration of T and NK cell effector function, and a significant reduction of tumor growth in various preclinical cancer models and clinical trials (78, 121). This evidence concerns the gene HAVCR2 and cancer.